» Articles » PMID: 24521857

Pathological Grading for Predicting Metastasis in Phaeochromocytoma and Paraganglioma

Overview
Specialties Endocrinology
Oncology
Date 2014 Feb 14
PMID 24521857
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

Phaeochromocytomas (PHEO) and paragangliomas are rare catecholamine-producing tumours. Although 10-30% of these tumours metastasise, histopathological criteria to discriminate malignant from benign tumours have not been established; therefore, reliable histopathological markers predicting metastasis are urgently required. A total of 163 tumours, including 40 metastatic tumours, collected by the Phaeochromocytoma Study Group in Japan (PHEO-J) were analysed using a system called grading system for adrenal phaeochromocytoma and paraganglioma (GAPP). The tumours were scored based on GAPP criteria as follows: histological pattern, cellularity, comedo-type necrosis, capsular/vascular invasion, Ki67 labelling index and catecholamine type. All tumours were scored from 0 to 10 points and were graded as one of the three types: well-differentiated (WD, 0-2 points), moderately differentiated (MD, 3-6 points) and poorly differentiated (PD, 7-10 points). GAPP scores of the non-metastatic and metastatic groups were 2.08±0.17 and 5.33±0.43 (mean±s.e.m., P<0.001) respectively. There was a significant negative correlation between the GAPP score and the interval until metastasis (r=-0.438, P<0.01). The mean number of years until metastasis after the initial operation was 5.5±2.6 years. The study included 111 WD, 35 MD and 17 PD types. The five-year survival of these groups was 100, 66.8 and 22.4% respectively. In addition, negative immunoreactivity for succinate dehydrogenase gene subunit B (SDHB) was observed in 13 (8%) MD or PD tumours and ten of the 13 (77%) had metastases. Our data indicate that a combination of GAPP classification and SDHB immunohistochemistry might be useful for the prediction of metastasis in these tumours.

Citing Articles

Metastatic Malignant Paraganglioma of Rare Sites Failed on Conventional Treatments Demonstrating Beneficial Response to Lu-DOTATATE PRRT.

Edamadaka Y, Bal M, Rane S, Parghane R, Basu S World J Nucl Med. 2025; 24(1):83-92.

PMID: 39959153 PMC: 11828642. DOI: 10.1055/s-0044-1791819.


A Pheochromocytoma With Adrenocorticotropic Hormone Secretion and Subsequent Fatal Outcome: A Case Report.

Nakabayashi H, Akiyama M, Yodokawa T, Itoh W, Taguchi A, Takeda K Cureus. 2025; 17(1):e77459.

PMID: 39958118 PMC: 11828756. DOI: 10.7759/cureus.77459.


Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma.

Ohmoto A, Shigematsu Y, Saito R, Dobashi A, Fujiwara Y, Togashi Y Virchows Arch. 2024; .

PMID: 39694932 DOI: 10.1007/s00428-024-04009-x.


Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution.

Ishizaki F, Taguchi T, Murata M, Hoshino S, Toba T, Takeda K Sci Rep. 2024; 14(1):26456.

PMID: 39488586 PMC: 11531473. DOI: 10.1038/s41598-024-75354-9.


The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease.

de Bresser C, de Krijger R Endocr Pathol. 2024; 35(4):279-292.

PMID: 39466488 PMC: 11659362. DOI: 10.1007/s12022-024-09830-3.